JOURNAL BROWSE
Search
Advanced SearchSearch Tips
BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia
Mundhofir, Farmaditya EP; Wulandari, Catharina Endah; Prajoko, Yan Wisnu; Winarni, Tri Indah;
  PDF(new window)
 Abstract
Specific patterns of the hereditary breast and ovarian cancer (HBOC) syndrome are related to mutations in the BRCA1 gene. One hundred unrelated breast cancer patients were interviewed to obtain clinical symptoms and signs, pedigree and familial history of HBOC syndrome related cancer. Subsequently, data were calculated using the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) risk prediction model. Patients with high score of BOADICEA were offered genetic testing. Eleven patients with high score of BOADICEA, 2 patients with low score of BOADICEA, 2 patient`s family members and 15 controls underwent BRCA1 genetic testing. Mutation screening using PCR-HRM was carried out in 22 exons (41 amplicons) of BRCA1 gene. Sanger sequencing was subjected in all samples with aberrant graph. This study identified 10 variants in the BRCA1 gene, consisting of 6 missense mutations (c.1480C>A, c.2612C>T, c.2566T>C, c.3113A>G, c.3548 A>G, c.4837 A>G), 3 synonymous mutations (c.2082 C>T, c.2311 T>C and c.4308T>C) and one intronic mutation (c.134+35 G>T). All variants tend to be polymorphisms and unclassified variants. However, no known pathogenic mutations were found.
 Keywords
HBOC syndrome;BRCA1 gene;Indonesian population;PCR-HRM;BOADICEA;
 Language
English
 Cited by
 References
1.
Akilzhanova A, Nyshanbekkyzy N, Nurkina Z, et al (2013). BRCA1 and BRCA2 gene mutations screening in sporadic breast cancer patients In Kazakhstan. Central Asian J Global Health, 2, 29.

2.
Azis F (2009). Gynecological cancer in Indonesia. J Gynecol Oncol, 20, 8-10. crossref(new window)

3.
Assi H, Khoury K, Dbouk H, et al (2013). Epidemiology and prognosis of breast cancer in young women. J Thorac Dis, 5, 2-8

4.
Beaber E, Buist D, Barlow W, et al (2014). Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res, 74, 4078-89. crossref(new window)

5.
Berzina D, Miklasevica M, Jekaterina Z, et al (2013). BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families. BMC Medical Genetics, 14, 61.

6.
Brown S, Morrison D, Cooke T (2009). Increasing incidence of breast cancer: distinguishing between the effects of birth cohort and a national breast screening programme. Breast Cancer Res Treat, 116, 603-7. crossref(new window)

7.
Cecchini R, Constantio J, Culey J, et al (2012). Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention Trials. Cancer Prev Res, 5, 583-92. crossref(new window)

8.
Cherbal F, Salhi N, Bakour R, et al (2012). BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families. Dis Markers, 32, 343-53. crossref(new window)

9.
Dombernowsky S, Weischer M, Freiberg J, et al (2009). Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev, 18, 2339-41. crossref(new window)

10.
Evans G, Howell A (2007). Breast cancer risk-assessment models. Breast Cancer Res, 9, 1750.

11.
Genetics Home Reference. 2013. BRCA1. Accessed December 15, 2013, at http://ghr.nlm.nih.gov/gene/BRCA1.

12.
Gierisch J, Coeytaux R, Urrutia R, et al (2014). Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev, 22, 1931-43.

13.
Glass A, Lacey J, Carreon J, et al (2007). Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screeningmammography, and estrogen receptor status. J National Cancer Institute, 99, 1152-61. crossref(new window)

14.
Haffty B, Choi D, Goyal S, et al (2009). Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. Ann Oncol, 20, 1653-9. crossref(new window)

15.
Hall M, Reid J, Burbidge L, et al (2009). BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer, 115, 2222-33. crossref(new window)

16.
Harianto, Mutiara R, Surachmat H (2005). The Risk of The Combination of Oral Contraception with Breast Cancer Incidence of Outpatient Clinic in Cipto Mangunkusumo Hospital. Majalah Ilmu Kefarmasian, 22, 84-99.

17.
Haryono S, Datasena I, Santosa W, et al (2015). A pilot genome-wide association study of breast cancer susceptibility loci in Indonesia. Asian Pac J Cancer Prev, 16, 2231-5. crossref(new window)

18.
Herrick B, Scally M, Madsen A, et al (2006). Natural selection and mammalian BRCA1 sequences: elucidating functionally important sites relevant to breast cancer susceptibility in humans. Mamm Genome, 17, 257-70. crossref(new window)

19.
Keshavarzi F, Javadi G, Zeinali S (2012). BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients. Familial Cancer, 11, 57-67. crossref(new window)

20.
Kwong A, On N, Wong C, et al (2012). Identification of BRCA1/2 founder mutations in southern Chinese breast cancer patients using gene sequencing and high resolution dna melting analysis. PLOS One, 7, 43994. crossref(new window)

21.
Kwong A, Shin V, Ho J, et al (2015). Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J Med Genet, 53, 103132.

22.
Leong S, Shen Z, Liu T, et al (2010). Is breast cancer the same disease in asian and western countries? World J Surg, 34, 2308-24. crossref(new window)

23.
Mary B, Jennifer E, Saundra B, et al (2012). NCCN clinical practice guidelines in oncology genetic/familial high-risk assessment: breast and ovarian version I. National Comprehensive Cancer Network.

24.
Matsuno R, Anderson W, Yamamoto S, et al (2007). Early- and late-onset breast cancer types among women in the united states and Japan. Cancer Epidemiol Bio-markers Prev, 16, 1437-42. crossref(new window)

25.
Medimegh I, Troudi W, Stambouli N, et al (2014). Wild-type genotypes of BRCA1 gene SNPs combined with micro RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases occurrence. Med Oncol, 31, 11.

26.
Mousavi S, Kasaeian A, Mansori K, et al (2013). Addressing the younger age at onset in breast cancer patients in asia: an age-period-cohort analysis of fifty years of quality data from the international agency for research on cancer. Oncol, 2013, 429862.

27.
Ng CH, Pathy B, Taib N, et al (2011). Comparison of breast cancer in Indonesia and Malaysia - a clinico-pathological study between Dharmais Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur. Asian Pac J Cancer Prev, 12, 2943-46.

28.
Nichols H, Trentham A, Egan K, et al (2009). Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev, 18, 1403-9. crossref(new window)

29.
Norsa'adah B, Rampal K, Rahman M, et al (2011). Diagnosis delay of breast cancer and its associated factors in Malaysian women. BMC Cancer, 11, 141. crossref(new window)

30.
Pathy N, Yip C, Taib N, et al (2011). Breast cancer in a multi-ethnic Asian setting: results from the Singapore-Malaysia hospital-based breast cancer registry. Breast, 20, S75-80.

31.
Petrucelli N, Daly M, Feldman G (2013). BRCA1 and BRCA2 hereditary breast and ovarian cancer.

32.
Pilarski R (2009). Cowden syndrome: a critical review of the clinical literature. J Genet Couns, 18, 13-27. crossref(new window)

33.
Pilato B, Martinucci M, Danza K, et al (2010). Mutations and polymorphic BRCA variants transmission in breast cancer familial members. Breast Cancer Res Treat, 125, 651-7.

34.
Purnomosari D, Pals G, Wahyono A, et al (2007). BRCA1 and BRCA2 germline mutation analysis in the Indonesian population. Breast Cancer Res Treat, 106, 297-304. crossref(new window)

35.
Schneider K, Garber J (2010). Li-Fraumeni syndrome. Acessed at November 25, 2014, at http://www.ncbi.nlm.nih.gov/books/NBK1311/.

36.
Sirait A, Oemiati R, Indrawati L (2009). Hubungan kontrasepsi pil dengan tumor/kanker payudara di Indonesia. Maj Kedokt Indon, 59, 348-56.

37.
Stahlbom A, Johansson H, Liljegren A, et al (2012). Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer. Familial Cancer, 11, 33-40. crossref(new window)

38.
Taib N, Yip C, Low W (2011). Recognising symptoms of breast cancer as a reason for delayed presentation in Asian women - The Psycho-socio-cultural Model for breast symptom appraisal: opportunities for intervention. Asian Pacific J Cancer Prev, 12, 1-8.

39.
UMD-BRCA1 mutations database.. 2015. BRCA1 gene mutation. Accessed April 15, 2015, at http://www.umd.be/BRCA1/

40.
Wahidin M, Noviani R, Hermawan S, et al (2012). Population-based cancer registry in Indonesia. Asian Pac J Cancer Prev, 13, 1709-10. crossref(new window)

41.
Yip C (2009). Breast cancer in Asia. Methods Mol Biol, 471, 51-64. crossref(new window)

42.
Yip C, Cazap E, Anderson B, et al (2010) Breast cancer management in middle-resourcecountries (MRCs): consensus statement from the breast health global initiative. Breast, 20, 12-9.

43.
Youlden D, Cramb S, Yip C, et al (2014). Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med, 11, 101-15.